Cg Oncology, Common Stock Performance
| CGON Stock | 34.75 0.65 1.91% |
The firm owns a Beta (Systematic Risk) of 1.73, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, CG Oncology, will likely underperform. CG Oncology, Common today owns a risk of 2.74%. Please confirm CG Oncology, Common potential upside, and the relationship between the jensen alpha and rate of daily change , to decide if CG Oncology, Common will be following its current price history.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days CG Oncology, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, CG Oncology, is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 1.91 | Five Day Return 2.36 | Year To Date Return (6.51) | Ten Year Return (6.51) | All Time Return (6.51) |
1 | We Think CG Oncology Can Afford To Drive Business Growth | 10/01/2024 |
2 | Acquisition by Song Hong Fang of 15600 shares of CG Oncology, at 36.63 subject to Rule 16b-3 | 10/07/2024 |
3 | Acquisition by Corleen Roche of 93600 shares of CG Oncology, at 36.63 subject to Rule 16b-3 | 11/01/2024 |
4 | Vanguard Group Incs Strategic Acquisition of CG Oncology Inc Shares | 11/04/2024 |
5 | CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates | 11/12/2024 |
6 | Avidity Partners Management LPs Strategic Acquisition in SCYNEXIS Inc | 11/15/2024 |
7 | CG Oncologys SWOT analysis bladder cancer stock poised for pivotal results | 11/21/2024 |
| Begin Period Cash Flow | 88.1 M |
CGON |
CG Oncology, Relative Risk vs. Return Landscape
If you would invest 3,537 in CG Oncology, Common on September 1, 2024 and sell it today you would lose (62.00) from holding CG Oncology, Common or give up 1.75% of portfolio value over 90 days. CG Oncology, Common is currently generating 0.0095% in daily expected returns and assumes 2.7377% risk (volatility on return distribution) over the 90 days horizon. In different words, 24% of stocks are less volatile than CGON, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CG Oncology, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CG Oncology,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CG Oncology, Common, and traders can use it to determine the average amount a CG Oncology,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0035
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CGON |
Estimated Market Risk
| 2.74 actual daily | 24 76% of assets are more volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average CG Oncology, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CG Oncology, by adding CG Oncology, to a well-diversified portfolio.
CG Oncology, Fundamentals Growth
CGON Stock prices reflect investors' perceptions of the future prospects and financial health of CG Oncology,, and CG Oncology, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CGON Stock performance.
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.16 | ||||
| Operating Margin | (658.02) % | ||||
| Current Valuation | 1.77 B | ||||
| Shares Outstanding | 67.63 M | ||||
| Price To Book | 4.30 X | ||||
| Price To Sales | 3,372 X | ||||
| Revenue | 204 K | ||||
| EBITDA | (55.43 M) | ||||
| Net Income | (48.61 M) | ||||
| Total Debt | 461 K | ||||
| Book Value Per Share | 7.95 X | ||||
| Cash Flow From Operations | (45.68 M) | ||||
| Earnings Per Share | (15.87) X | ||||
| Market Capitalization | 2.31 B | ||||
| Total Asset | 199.3 M | ||||
| Retained Earnings | (129.94 M) | ||||
| Working Capital | 179.87 M | ||||
About CG Oncology, Performance
By examining CG Oncology,'s fundamental ratios, stakeholders can obtain critical insights into CG Oncology,'s financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that CG Oncology, is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.24) | (0.26) | |
| Return On Capital Employed | (0.30) | (0.31) | |
| Return On Assets | (0.24) | (0.26) | |
| Return On Equity | (0.26) | (0.28) |
Things to note about CG Oncology, Common performance evaluation
Checking the ongoing alerts about CG Oncology, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CG Oncology, Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CG Oncology, Common has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 204 K. Net Loss for the year was (48.61 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| CG Oncology, generates negative cash flow from operations | |
| CG Oncology, Common has a frail financial position based on the latest SEC disclosures | |
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: NRG Energy, Inc. Given Consensus Recommendation of Moderate Buy by Analysts |
- Analyzing CG Oncology,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CG Oncology,'s stock is overvalued or undervalued compared to its peers.
- Examining CG Oncology,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CG Oncology,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of CG Oncology,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CG Oncology,'s stock. These opinions can provide insight into CG Oncology,'s potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CG Oncology, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CG Oncology,. If investors know CGON will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CG Oncology, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (15.87) | Revenue Per Share 0.015 | Quarterly Revenue Growth 3.778 | Return On Assets (0.16) | Return On Equity (0.20) |
The market value of CG Oncology, Common is measured differently than its book value, which is the value of CGON that is recorded on the company's balance sheet. Investors also form their own opinion of CG Oncology,'s value that differs from its market value or its book value, called intrinsic value, which is CG Oncology,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CG Oncology,'s market value can be influenced by many factors that don't directly affect CG Oncology,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CG Oncology,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if CG Oncology, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CG Oncology,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.